This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
NUFYMCO BLA has been approved by the USFDA
The company also reported significant progress toward its internally defined Sustainable Development Goals
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
Subscribe To Our Newsletter & Stay Updated
